Allergan Takes Aim At Lupin Over Lumigan ANDA

Law360, New York (November 14, 2011, 6:02 PM EST) -- Pharmaceutical giant Allergan Inc. on Friday sued a subsidiary of Indian drugmaker Lupin Ltd. in Texas federal court alleging infringement of a patent for glaucoma medication Lumigan in an ongoing bid to protect the drug from generic competition.

Allergan alleged that Lupin Pharmaceuticals Inc. infringed U.S. Patent Number 7,851,504, "Enhanced bimatoprost ophthalmic solution," when the drugmaker filed an abbreviated new drug application with the U.S. Food and Drug Administration seeking approval to produce and sell a generic version of Lumigan.

Lupin Pharmaceuticals claims in its ANDA...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.